A research study centered on magic mushrooms in Canada found that almost 80% of participants advocated for the use of psilocybin as a medical treatment for individuals in distress. In fact, two-thirds of these Canadian participants concurred that psilocybin should be legally accessible for those who require it.
Beyond merely endorsing the substance’s availability, a striking 84.8 percent of participants voiced their opinion that the public health system should bear the expenses of such treatments. A significant number of Canadians view psilocybin as a feasible alternative, especially for the alleviation of end-of-life distress.
[toc]
Principal Findings:
- Inhabitants of Québec, Ontario, Alberta, and British Columbia recognize psilocybin as a legitimate medical option for treating end-of-life existential distress.
- Magic mushrooms are deemed safe for use in treating existential distress.
- Participants in two double-blind trials experienced immediate and long-lasting benefits, with effects persisting for six months or even more.
Decoding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals grapple with their mortality. Patients may undergo feelings of helplessness, isolation, anxiety, and a loss of purpose. This form of distress particularly impacts patients with life-threatening diseases, potentially leading them to hasten death or contemplate suicide.
Mostly, individuals confronted with terminal diseases or major life changes are the ones who experience this kind of distress. It profoundly affects their mental health and overall life quality.
Existential therapy aims to address problems such as anxiety, depression, grief, loneliness, indifference, despair, identity confusion, and feelings of purposelessness and existential fear. However, it might necessitate multiple sessions and may not prove effective for everyone.
The inconsistency in the effectiveness of such therapy is a main reason why many individuals seek alternative treatments.
Health Canada’s Stance on Psilocybin for Treatment Purposes
In the last two decades, preliminary clinical trials have highlighted the potential advantages of using psychedelic substances, particularly psilocybin, to treat complex mental disorders. It has been found that psilocybin can quickly and permanently alleviate existential distress in patients approaching end-of-life.
Recognizing the possible efficacy of these suggested hallucinogenic mushrooms, especially when conventional treatments are ineffective, Health Canada updated the Special Access Program in 2022. This update enables healthcare professionals to apply for controlled substances for their patients.
Canadian Support for Access to Psilocybin
A research piece presented in the Palliative Care Journal evaluates societal views on psilocybin-aided therapy for end-of-life care. The data from the study includes:
| Methodology | Input from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia; 19% of these participants had used psilocybin before (15% from Québec, 26% from British Columbia). |
| Findings | 79.3% view psilocybin-assisted therapy as a legitimate medical option for treating end-of-life existential distress. 63.3% think psilocybin should be integrated into medical treatment. 84.8% endorse the public health system providing this therapy. 44.2% believe healthcare professionals should administer the substance without needing Health Canada’s supervision. |
The outcomes align with surveys conducted in Canada, England, and Australia. The researchers stressed that their research is distinctive because it primarily focuses on the use of psychoactive substances for managing existential distress during end-of-life situations.
Why Canadians Support Psilocybin Use
Increasing numbers of Canadians are supporting the use of psilocybin for treatment, primarily driven by evidence from esteemed research institutions. The general perception of psilocybin mushrooms as safe for relieving existential distress also contributes to this support. In various studies, participants have not reported severe adverse health effects, such as multiple organ failure.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients received a high dose of psilocybin and a low dose as an active placebo control | Immediate and durable The effectiveness of this therapy can be attributed mainly to the mystical experiences it provides, such as a sense of unity and profound emotional insights, which can last up to six months or even longer. |
| New York University Study | In this trial, 29 patients were randomly chosen either to receive psilocybin or an active placebo, niacin. | The results of this study were consistent with those of the Johns Hopkins study. Patients who received psilocybin reported experiencing psychological relief and a new outlook on life and death. |
| BMC Palliative Care Study | The study conducted interviews with nineteen participants, including 7 doctors, 4 nurses, 4 chaplains, 3 social workers, and a psychologist. The aim was to understand how professionals in palliative care perceive existential distress and their views on psychedelic therapy as a potential treatment. | From the perspective of the palliative care professionals, psychedelic-assisted therapy (PAT) could potentially help alleviate existential distress. |
Patient Experiences
Support for the effectiveness of psilocybin doesn’t only come from scientific studies. Many patient stories also highlight its potential to improve mental health and overall quality of life.
The Journey of Yokoi
Mio Yokoi, who was diagnosed with terminal stage 4 pancreatic cancer, shares her transformative experience during her assisted therapy. She visualized herself on a raft, surrounded by nature and whimsical creatures, which cultivated a profound understanding of the universe’s interconnectedness and support. This vision brought her immense peace and affirmation.
Despite receiving traditional mental health support, Yokoi’s anxiety and distress persisted post-diagnosis. Psilocybin therapy allowed her to reconnect with her body and provided her with a tangible sense of love and support, greatly improving her emotional and mental health.
The Story of Chrissy
Chrissy, a 50-year-old woman, was diagnosed with stage 4 breast cancer, which had spread to her lungs. At the time of the study, she was working full-time as an administrative supervisor in healthcare and identified as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Following the therapy, Chrissy reported significant reductions in anxiety, depression, fear of death, hopelessness, and demoralization. When asked about any changes in her religious or spiritual beliefs post-therapy, she responded that the experiences added depth and authenticity to her beliefs.
Brenda’s Journey
In the course of her therapy sessions, Brenda experienced a simulated death twice. These experiences led her to perceive death as a beautiful part of life’s journey, eliminating her fear of it. She accredited the study for initiating her healing process from childhood traumas. The data collected corroborated her profound transformation.
Consequently, a decrease in anxiety and death-related fear, coupled with an increase in spirituality, were observed.
Availability of Magic Mushroom Products in Canada
The accessibility of psilocybin capsules and other related products designed for managing existential anxiety and other mental health issues might be limited. Nevertheless, reliable online dispensaries serve as a viable source for these products when needed.
| Attribute | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some adjacent South American nations. | Discovered in Cambodia, near the vicinity of the Angkor Wat Temple. | Associated with the Penis Envy mushrooms, which rose to fame in the 1970s. |
| Strength | Moderately potent; suitable for beginners. | Similarly moderate in potency; perfect for newcomers. | Highly potent; best suited for those with intermediate to advanced experience. |
| Effects | Triggers a mental euphoria, mild confusion, enhanced color perception, joyous feelings, spiritual experiences, increased creativity, and improved concentration. | Causes an energizing and long-lasting high, minor visual changes, enhanced creativity, euphoria, a gentle physical high, fractal imagery, and sensations of joy. | Induces profound shamanic experiences, vision quests, intense mystical experiences, increased creativity, focus, social awareness, and mood upliftment. |
Mitigate End-of-life Anxiety with Psilocybin Products
Existential or end-of-life distress can impose a substantial burden on many patients nearing the end of their lives. Conventional treatments for this distress may not always be effective, leading to increased support in Canada for wider access to magic mushrooms within public healthcare. This growing public interest could We urge regulatory authorities to evaluate the potential of magic mushrooms as a credible treatment option. Obtain your psychedelics and shroom delivery from Magic Mushrooms Edmonton Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
The experience of Psychedelic-assisted therapy (PAT) is highly individualized, and adherence to specific protocols is crucial for a positive outcome. Patients are required to undergo comprehensive screening and mental preparedness before using the substance.
- Preparation before the Session: Patients partake in a thorough evaluation. The therapist converses with the patient about their objectives and expectations to set intentions for the session. The patient is briefed by the therapist about the process and what they should expect during the session.
- The Session: A controlled dose of the substance is given to the patients in a calm, distraction-free environment to promote relaxation and introspection. The therapist continuously provides support and guidance throughout this period.
- Post-Session Integration Therapy: This therapy facilitates the patient in interpreting and assimilating their experiences. Follow-up sessions ensure sustained support and counselling to solidify the insights and transformations achieved during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin engages with the brain by adhering to serotonin receptors, particularly the 5-HT2A receptor. This interaction can cause alterations in perception, mood, and cognition, leading to significant shifts in consciousness, emotional breakthroughs, and novel perspectives.
Is psilocybin therapy available to everyone?
Psilocybin therapy isn’t appropriate for everyone. Patients with specific mental health conditions or existential distress are thoroughly screened, excluding those with a history of psychosis.
Related Articles:
